Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

The 2022 OncoAlert Colloquium Day 2: GU Oncology

The 2022 OncoAlert Colloquium

23 - 28 Jan 2023

Published: 31 Jan 2023

Views: 95

Rating:

Save

Dr Gilberto Morgan - Skåne University Hospital in Lund, Sweden

Dr Gilberto Morgan introduces the second day (24th January) of the 2022 OncoAlert Colloquium.

Day two of the Colloquium focusing on the best in GU Oncology 2022 and hosts the following key speakers:

Dr Gilberto Morgan of OncoAlert discussing 'FDA approvals in 2022 and corresponding trials'.

Dr Toni Choueiri (Dana Farber, Boston, USA) discussing 'Kidney Cancer'.

Dr Neeraj Agarwal (Huntsman Institute, Salt Lake City, USA) discussing 'Prostate Cancer'.

Dr Petros Grivas (University of Washington, Seattle, USA) discussing 'Bladder Cancer'.

Dr Sean McBride (Memorial Sloan Kettering, New York, USA) discussing 'GU Radiation Therapy on the ASTRO session'.

Mr Bryan Lewis (KidneyCan, USA) discussing 'The Patient Perspective in Kidney Cancer'.

Dr John Haanen (Netherlands Cancer Institute, Amsterdam, Netherlands) discussing 'Immuno Oncology in 2022'.

Finishing off with with a MASCC Session by Dr Florian Scotte (Gustave Roussy, Villejuif, France) discussing 'Targeted Therapy Toxicities'.

Related Videos

Prostate cancer

Dr Alison Tree - Institute of Cancer Research, London, UK

Prostate cancer ( Dr Alison Tree - Institute of Cancer Research, London, UK )

Gaza's cancer patients: Navigating the dual struggle of illness and war

Dr Ru'a Rimawi - Dana-Farber Cancer Institute, Boston, United States of America

Gaza's cancer patients: Navigating the dual struggle of illness and war ( Dr Ru'a Rimawi - Dana-Farber Cancer Institute, Boston, United States of America )

Cancer in emergencies: What can we do better to protect the most vulnerable?

Prof Tezer Kutluk - Turkish Association for Cancer Research and Control, Ankara, Turkey

Cancer in emergencies: What can we do better to protect the most vulnerable? ( Prof Tezer Kutluk - Turkish Association for Cancer Research and Control, Ankara, Turkey )

ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer

Prof Karim Fizazi, Dr Anders Bjartell, Dr Niven Mehra and Prof Eleni Efstathiou

ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer ( Prof Karim Fizazi, Dr Anders Bjartell, Dr Niven Mehra and Prof Eleni Efstathiou )

Grand Rounds: Improving quality of patient-centred care

Dr Didier Verhoeven, Prof Nirmala Bhoo Pathy and Dr Luzia Travado

Grand Rounds: Improving quality of patient-centred care ( Dr Didier Verhoeven, Prof Nirmala Bhoo Pathy and Dr Luzia Travado )

OncoAlert Round Up for September 15-21, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert Round Up for September 15-21, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

The iCCaRE Consortium for Black Men - Addressing the disproportionate burden of prostate cancer

Mr Arnold Merriweather, Dr Che Ngufor and Dr Folakemi Odedina

The iCCaRE Consortium for Black Men - Addressing the disproportionate burden of prostate cancer ( Mr Arnold Merriweather, Dr Che Ngufor and Dr Folakemi Odedina )

Choosing Wisely in radiology Tanzania

Dr Revelian Iramu - Ocean Road Cancer Institute, Dar es Salaam, Tanzania

Choosing Wisely in radiology Tanzania ( Dr Revelian Iramu - Ocean Road Cancer Institute, Dar es Salaam, Tanzania )

Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant tumours

Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Houston, USA

Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant tumours ( Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Houston, USA )

More from ecancer